BPMX - BioPharmX Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
0.8855
-0.0081 (-0.91%)
At close: 4:00PM EDT

0.8855 0.00 (0.00%)
Pre-Market: 6:23AM EDT

Stock chart is not supported by your current browser
Previous Close0.8936
Open0.9500
Bid0.0000 x 900
Ask0.0000 x 800
Day's Range0.8300 - 0.9500
52 Week Range0.8100 - 6.7500
Volume631,914
Avg. Volume637,617
Market Cap9.46M
Beta (3Y Monthly)0.46
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Can We See Significant Institutional Ownership On The BioPharmX Corporation (NYSEMKT:BPMX) Share Register?
    Simply Wall St.3 months ago

    Can We See Significant Institutional Ownership On The BioPharmX Corporation (NYSEMKT:BPMX) Share Register?

    Every investor in BioPharmX Corporation (NYSEMKT:BPMX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend toRead More...

  • Is BioPharmX Corporation’s (NYSEMKT:BPMX) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.7 months ago

    Is BioPharmX Corporation’s (NYSEMKT:BPMX) Balance Sheet Strong Enough To Weather A Storm?

    BioPharmX Corporation (NYSEMKT:BPMX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is BPMX will Read More...

  • Who Are The Major Shareholders In BioPharmX Corporation (NYSEMKT:BPMX)?
    Simply Wall St.9 months ago

    Who Are The Major Shareholders In BioPharmX Corporation (NYSEMKT:BPMX)?

    The big shareholder groups in BioPharmX Corporation (NYSEMKT:BPMX) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies.Read More...

  • What Pushed BioPharmX Stock Up Yesterday?
    Market Realist11 months ago

    What Pushed BioPharmX Stock Up Yesterday?

    On July 19, specialty dermatology player BioPharmX (BPMX) announced that the FDA had waived the dermal carcinogenicity study it had required as part of the development program for BPX-01. BPX-01 is BioPharmX’s investigational topical minocycline gel for the treatment of patients suffering from inflammatory lesions due to acne vulgaris. The waiver implies that BioPharmX will save in terms of the time and resources that would have been required for the nonclinical research normally done for the FDA review.